Botanix Pharmaceuticals (ASX:BOT) announced financial results for the quarter ended 30 September 2022.
Submission of New Drug Application (NDA) for FDA approval for Sofpironium Bromide successfully completed.
Successful A$7.5m placement to institutions and sophisticated investors, including directors of the Board.
Positive data announced for BTX 1702 rosacea Phase 1b/2 randomised, double blinded, vehicle controlled clinical study.
$10.1 million cash at end of quarter.
Following the announcement the company?s share price unchanged.